ALXO
ALX Oncology Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.01
−0.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 150.0K | — | — | — | — |
| Gross Profit | (150.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 61.8M | 77.0M | 116.4M | 141.8M | 98.4M |
| SG&A Expense | 21.0M | 23.9M | 26.1M | 28.5M | 29.0M |
| General & Admin Expense | 21.0M | 23.9M | 26.1M | 28.5M | 29.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (388.0K) | 3.2M | — | — | — |
| Total Operating Expenses | 82.4M | 104.0M | 142.5M | 170.3M | 127.4M |
| Cost and Expenses | 82.6M | 104.0M | 142.5M | 170.3M | 127.4M |
| Operating Income (EBIT) | (82.6M) | (104.0M) | (142.5M) | (170.3M) | (127.4M) |
| Non-Operating | |||||
| Interest Income | 4.1M | 4.0M | 9.4M | 10.6M | 4.3M |
| Interest Expense | 1.4M | 1.6M | 1.7M | 1.6M | 238.0K |
| Net Interest Income | 2.7M | 2.4M | 7.6M | 9.1M | 4.0M |
| Other Non-Op Income/Expense | 1.7M | 2.3M | 7.6M | 9.5M | 4.0M |
| Non-Operating Income (excl Interest) | (3.1M) | (3.9M) | (9.3M) | (11.0M) | (4.3M) |
| EBT (Pre-Tax Income) | (80.9M) | (101.7M) | (134.8M) | (160.8M) | (123.4M) |
| Income Tax Expense | — | — | — | — | 64.0K |
| Bottom Line | |||||
| Net Income | (80.9M) | (101.7M) | (134.8M) | (160.8M) | (123.5M) |
| Earnings from Cont. Ops | (80.9M) | (101.7M) | (134.8M) | (160.8M) | (123.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (80.9M) | (101.7M) | (134.8M) | (160.8M) | (123.5M) |
| Per Share | |||||
| Basic EPS | ($1.13) | ($1.90) | ($2.58) | ($3.74) | ($3.03) |
| Diluted EPS | ($1.13) | ($1.90) | ($2.58) | ($3.74) | ($3.03) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 135.6M | 53.7M | 52.2M | 43.0M | 40.7M |
| Diluted Shares Outstanding | 135.6M | 53.7M | 52.2M | 43.0M | 40.7M |
| Profitability Metrics | |||||
| EBITDA | (78.9M) | (99.4M) | (132.2M) | (158.4M) | (122.8M) |
| D&A | 554.0K | 706.0K | 872.0K | 836.0K | 342.0K |
| EBIT | (79.5M) | (100.1M) | (133.1M) | (159.2M) | (123.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026